6505--Pluvicto and Lutathera | VA GLA
Closed Special Notice Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- 36C26225Q1321
- Agency
-
Veterans Integrated Service Network 22
Veterans Health Administration, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Los Angeles, California 90073, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs Network Contracting Office 22, located in Long Beach, California, has issued a Special Notice of Intent to Sole Source for the procurement of two radiopharmaceutical products from Novartis Pharmaceuticals Corporation. The notice pertains to the VA Greater Los Angeles Healthcare System's requirement to purchase Pluvicto Lutetium Lu 177 Vipivotide Tetra (105 units) and Lutathera Lutetium Lu 177 Dotatate (10 units) under Federal Supply Class 6505 and NAICS code 325412. These radiopharmaceuticals are intended for treating advanced prostate cancer and neuroendocrine tumors respectively at the VA Greater Los Angeles Nuclear Medicine Service. The procurement is being conducted under FAR Part 8.405-6(a)(1)(B) as an "Only One Available Source" acquisition, with Novartis being the intended sole source contractor based on their existing contract 36F79720D0180 awarded on July 30, 2020.
The primary purpose of this notice is to inform industry contractors of the government's intent to execute a sole source delivery order while providing an opportunity for other potential suppliers to demonstrate their capabilities. Interested parties must submit capabilities statements by 10:00 AM Pacific Time on August 15, 2025, to the designated point of contact, Hestia Sim, via email with the specific subject line format. To be considered, responding companies must provide clear and compelling evidence that they can supply the same items and services, demonstrating that competition would be advantageous to the government. The notice emphasizes that this is not a formal solicitation or request for competitive proposals, and no award will be made based on unsolicited quotations received in response to this notice. The government retains sole discretion in determining whether to proceed with competitive procurement based on any responses received.
Notice text
NOTICE OF INTENT TO SOLE SOURCE
This notice is being published in accordance with Federal Acquisition Regulation (FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. This is a notice of intent to award a sole source contract and is not a request for competitive quotes/proposals. The Department of Veterans Affairs, Network Contracting Office (NCO) 22, located at 4811 Airport Plaza Drive, Long Beach, CA is issuing this Notice of Intent (NOI) to inform industry contractors of the Government’s intent to execute a Sole Source Delivery Order under FAR Part 8, specifically FAR Part 8.405-6(a)(1)(B), Only One Available Source. The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1,300 Employees.
The intended contractor is Novartis Pharmaceuticals Corporation located at 59 Route 10, East Handover, NJ 07936. Place of Performance is the VA Greater Los Angeles Healthcare System located at 11301 Wilshire Blvd, Los Angeles, CA 90073. VA Greater Los Angeles Nuclear Medicine Service intends to purchase PLUVICTO LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML and LUTATHERA LUTETIUM LU 177 DOTATATE in quantities listed below:
NDC#
Contract
Description
Qty
UOM
69488-0010-61
36F79720D0180
PLUVICTO LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML
105
EA
69488-0003-01
36F79720D0180
LUTATHERA LUTETIUM LU 177 DOTATATE
10
EA
VA Greater Los Angele Healthcare System Nuclear Medicine Service requires Pluvicto to treat advance prostate cancer and Lutathera to treat neuroendocrine tumor therapy. Radiopharmaceuticals requested were awarded to Novartis Pharmaceuticals Corporations on 7/30/2020 under contract 36F79720D0180.
This notice of intent is neither a formal solicitation nor a request for competitive proposals. No solicitation document is available and telephone requests will not be honored. No award will be made on the basis of unsolicited quotations or offers received in response to this notice. Any response to this notice must show clear and compelling evidence that the responding company can provide the same items/services, and that competition will be advantageous to the Government. The intent of this synopsis is for informational purposes only. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination by the Government not to compete this action based on this notice is solely within the discretion of the Government.
All inquiries and concerns must be addressed in writing via e-mail to Hestia Sim, Hestia.Sim@va.gov with RESPONSE TO INTENT TO SOLE SOURCE Pluvicto and Lutathera in the subject line. All interested parties who are responsible, certified, and capable may identify their interest and may submit a capabilities statement no later than 10:00 AM Pacific Local Time August 15, 2025, to the above-mentioned point of contact. The interested parties bear full responsibility to ensure complete transmission and timely receipt. The Department of Veterans Affairs will NOT be responsible for any costs incurred by interested parties in responding to this notice of intent.
Files
| File | Type | Posted |
|---|---|---|
| S02 36C26225Q1321.docx | DOCX document |
Notice history
| Notice | Type | Posted |
|---|---|---|
| 6505--Pluvicto and Lutathera | Award Notice | |
| This notice | Special Notice |
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity